
About Dyno Therapeutics
Dyno Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2018. AI-based AAV engineering for gene therapy delivery is provided. Dyno Therapeutics has raised $109 million across 2 funding rounds from investors including Andreessen Horowitz, Casdin Capital and Google Ventures. The company has 38 employees. Its website dynotx.com draws about 14 thousand monthly visits. Dyno Therapeutics offers products and services including bCap 1, eCap 1, and Platform. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2018 and based in Cambridge, United States, operations in the biotechnology sector are focused on AAV engineering through AI and data-driven methods. Vectors are developed for safe, targeted in vivo gene therapy delivery. Next-generation DNA synthesis of AAV capsids is combined with high-throughput sequencing and machine learning. Relationships between capsid sequences and functions are mapped, while vectors are optimized for enhanced therapeutic outcomes.
- Headquarters Cambridge, United States
- Employees 38
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Website dynotx.com
- Social LinkedIn X
- Total Equity Funding$109M (USD)
in 2 rounds
- Latest Funding Round$100M (USD), Series A
May 2021
- InvestorsAndreessen Horowitz
& 7 more
- Employee Count38
Products & Services of Dyno Therapeutics
Dyno Therapeutics offers a comprehensive portfolio of products and services, including bCap 1, eCap 1, and Platform.
AI-designed vector for targeted gene delivery in therapies
AI-powered vector for enhanced gene therapy applications
System for discovering novel gene therapy vectors using AI
Funding Insights of Dyno Therapeutics
Dyno Therapeutics has successfully raised a total of $109M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $100 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $109M
- Total Rounds 2
- Last Round Series A β $100M
- First Round $9M
(May 2020)
- Investors Count 8
All 2 funding rounds of Dyno Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $100M | Series A | β | a16z | |
| May 2020 | $9M | Seed | β | Polaris Partners, CRV | β |
8 investors in total: 8 institutional.
Investors in Dyno Therapeutics
Dyno Therapeutics has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Andreessen Horowitz, Casdin Capital and Google Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Provider of venture capital investments across planetary, human, and economic health | obvious.com | San Francisco, United States | ||
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Early-stage investments are made in frontier science ventures. | kdtvc.com | Black Mountain, United States | ||
CRV is recognized as a venture capital firm investing in technology startups. | crv.com | Palo Alto, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States |
Investor details for Dyno Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dyno Therapeutics
62 people are tracked at Dyno Therapeutics (10 in leadership, 6 in board & advisors, 46 in team); the tracked headcount is 38.
| Name | Role | Group |
|---|---|---|
Eric Kelsic | CEO & Co-Founder | Leadership |
Tyson Bertmaring | VP, Head of Stewardship | Leadership |
Yvette Leung | VP, Business Development | Leadership |
Kosta Kleitsas | VP, Head of People | Leadership |
David Levy-Booth | Associate Director | Leadership |
Sam Sinai | VP, Deep Learning Research & Co-Founder | Leadership |
Russ Katz | Manager, Chief of Staff | Leadership |
Rebecca Servais | Director, Operations | Leadership |
Daniela Pignatta | Director, Experimental Science | Leadership |
Carrie Adams | Associate People Director | Leadership |
Tomas Bjorklund | Scientific Co-founder & Scientific Advisor | Board & advisors |
Debora S. Marks | Scientific Advisor | Board & advisors |
Nicole Paulk | Scientific Advisor | Board & advisors |
Alan Crane | Co-Founder & Executive Chairman | Board & advisors |
Adrian Veres | SVP, Experimental Science & Co-Founder | Board & advisors |
George Church | Scientific Co-founder & Scientific Advisor | Board & advisors |
Carey Twynman | Senior Talent Acquisition Specialist, People Team | Team |
Viktoria Betin | Principal Scientist, Experimental Science | Team |
Elina Locane | Senior Scientist, Computational Science | Team |
Michael Robinson | Senior RA, Experimental Science | Team |
42 more people are available in the full profile.
Complete people profiles for Dyno Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Dyno Therapeutics
3 dated milestones of Dyno Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Dyno Therapeutics is founded.
- Funding First funding round of $9.0M.
- Funding Latest funding round, Series A, of $100.0M.
Competitors of Dyno Therapeutics
Dyno Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Dyno Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dyno Therapeutics
The website of Dyno Therapeutics (dynotx.com) receives about 14.4K visits a month and ranks #2,089,404 among all websites worldwide, #2,855 in Biotechnology and Pharmaceuticals.
- Monthly visits14.4K
▲ 35.5% vs previous month
- Unique visitors4.8K
per month
- Global rank#2,089,404
among all websites
- Category rank#2,855
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.9
- Average visit14 sec
- DevicesDesktop 33% Β· Mobile 67%
Websites whose visitors overlap most with Dyno Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sherlock.bio | 100% | 2.8K | #4,929,420 | View details | |
| cuebiopharma.com | 97% | 4.9K | #7,063,180 | View details | |
| ornatx.com | 96% | 4.4K | #3,250,511 | View details | |
| bioagilytix.com | 94% | 41.6K | #919,146 | View details | |
| dayzerodiagnostics.com | 93% | 1.4K | #5,790,285 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 18 similar websites and full traffic analytics for Dyno Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Dyno Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dyno Therapeutics
Complete news archive for Dyno Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dyno Therapeutics
Dyno Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Dyno Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Dyno Therapeutics is a funded company, having raised a total of $109M across 2 funding rounds to date. The company's 1st funding round was a Seed of $9M, raised on May 2020.
Dyno Therapeutics has 38 employees.
Founded in 2018 and based in Cambridge, United States, operations in the biotechnology sector are focused on AAV engineering through AI and data-driven methods. Vectors are developed for safe, targeted in vivo gene therapy delivery. Next-generation DNA synthesis of AAV capsids is combined with high-throughput sequencing and machine learning. Relationships between capsid sequences and functions are mapped, while vectors are optimized for enhanced therapeutic outcomes.
Dyno Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Dyno Therapeutics offers bCap 1, eCap 1, and Platform.
Dyno Therapeutics has 8 investors. Key investors include Andreessen Horowitz, Casdin Capital, Google Ventures, Obvious Ventures, and Lux Capital.
